Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response

Cell Cycle. 2011 May 1;10(9):1499-501. doi: 10.4161/cc.10.9.15423. Epub 2011 May 1.

Authors

Alejandro Vazquez-Martin¹, Cristina Oliveras-Ferraros, Sílvia Cufí, Begoña Martin-Castillo, Javier A Menendez

Affiliation

¹ Catalan Institute of Oncology (ICO), and Girona Biomedical Research Institute (IDIBGI), Catalonia, Spain.

PMID: 21566461
DOI: 10.4161/cc.10.9.15423

No abstract available

Publication types

Letter

MeSH terms

Ataxia Telangiectasia Mutated Proteins
Carcinoma, Squamous Cell / enzymology
Carcinoma, Squamous Cell / genetics
Carcinoma, Squamous Cell / pathology*
Cell Cycle Proteins / genetics*
Cell Cycle Proteins / metabolism
Cell Line, Tumor
Checkpoint Kinase 2
DNA Damage / drug effects
DNA Damage / genetics
DNA-Binding Proteins / genetics*
DNA-Binding Proteins / metabolism
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / genetics
Diabetes Mellitus, Type 2 / pathology*
Enzyme Activation / drug effects
Enzyme Activation / genetics
Humans
Metformin / pharmacology*
Protein Serine-Threonine Kinases / genetics*
Protein Serine-Threonine Kinases / metabolism
Protein Serine-Threonine Kinases / physiology*
Tumor Suppressor Proteins / genetics*
Tumor Suppressor Proteins / metabolism

Substances

Cell Cycle Proteins
DNA-Binding Proteins
Tumor Suppressor Proteins
Metformin
Checkpoint Kinase 2
ATM protein, human
Ataxia Telangiectasia Mutated Proteins
CHEK2 protein, human
Protein Serine-Threonine Kinases